Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06837571 · ClinicalTrials.gov registry record

Methadone Dose Monitoring With a Remote Medication Monitor

A clinical trial, sponsored by Cari Health.

Not yet
Registry status
30
Enrollment target

NCT06837571: Clinical Trial study, sponsored by Cari Health.

NCT06837571 is a clinical trial that has not yet begun recruiting, run by Cari Health. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06837571 has not yet begun recruiting, sponsored by Cari Health.

NOT YET RECRUITING
Registry status
30 participants
Enrollment target

Study Summary

Proof of concept: Pilot Study A Pilot, proof of concept, observational study with a long-term goal to develop a minimally invasive wearable Remote Medication Monitor (RMM) that provides continuous, real-time data on methadone levels in interstitial fluid (ISF). An RMM could be used as a medication adherence monitor and would allow for the physician, counselor, patient, or family member to remotely verify that a physician-prescribed dose has been taken.

Primary Outcome

measure dermal interstitial fluid with LC-MS for methadone before and after a daily dose

Interventions

  • DIAGNOSTIC_TEST Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo
  • DRUG Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo
  • DEVICE ISF Extraction Device 2

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-04-26
Est. Completion 2025-06
Cari Health

3 total trials

What is known before NCT06837571 opens enrollment

NCT06837571 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.

The record links to 0 conditions, and to 3 interventions - of which Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo is the first listed.

NCT06837571 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06837571 about?

NCT06837571 is a clinical study titled "Methadone Dose Monitoring With a Remote Medication Monitor". Proof of concept: Pilot Study A Pilot, proof of concept, observational study with a long-term goal to develop a minimally invasive wearable Remote Medication Monitor (RMM) that provides continuous, real-time data on methadone levels in interstitial fluid (ISF). An RMM could be used as a medication ...

What is the current status of trial NCT06837571?

This trial is currently not yet recruiting. The enrollment target is 30 participants. The study started on 2025-04-26. Estimated completion is 2025-06.

What interventions are being tested in trial NCT06837571?

The interventions under investigation include: Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo (DIAGNOSTIC_TEST), Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo (DRUG), ISF Extraction Device 2 (DEVICE).

Who is sponsoring clinical trial NCT06837571?

This trial is sponsored by Cari Health, which has 3 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06837571, the US trial registry maintained by the National Library of Medicine. NCT06837571 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.